Mavrilimumab to reduce progression of acute respiratory failure in patients with severe COVID-19 pneumonia and systemic hyper-inflammation

Phase II clinical trial of GM-CSF-receptor antibody or placebo in patients with COVID-19 pneumonia and hyper-inflammation

The study hypothesis is that early treatment with mavrilumumab can reduce fever and prevent progression to severe respiratory failure and death in patients with severe COVID-19 pneumonia and clinical and biological features of hyperinflammation.
Target Population
Severe COVID-19 Pneumonia and Systemic Hyper-inflammation
Primary Investigator
Contact Email
Sponsor
Study Type
Treatments and Interventions
Clinicaltrials.gov Status
Pre-clinicaltrials.gov
Current Study Status
Not yet recruiting
Current Study Phase
Phase 2
Clinical Trial Network Utilization
No
Accrual Target Number
60
CTSA Support
Yes